220 related articles for article (PubMed ID: 34575025)
41. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
42. The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape.
Weinberg DN; Papillon-Cavanagh S; Chen H; Yue Y; Chen X; Rajagopalan KN; Horth C; McGuire JT; Xu X; Nikbakht H; Lemiesz AE; Marchione DM; Marunde MR; Meiners MJ; Cheek MA; Keogh MC; Bareke E; Djedid A; Harutyunyan AS; Jabado N; Garcia BA; Li H; Allis CD; Majewski J; Lu C
Nature; 2019 Sep; 573(7773):281-286. PubMed ID: 31485078
[TBL] [Abstract][Full Text] [Related]
43. [Genetic characteristics and clinical outcomes of pediatric acute myeloid leukemia with NUP98-NSD1 fusion gene].
Wang T; Ni JB; Wang XY; Dai Y; Ma XL; Su YC; Gao YY; Chen X; Yuan LL; Liu HX
Zhonghua Yi Xue Za Zhi; 2019 Sep; 99(36):2820-2825. PubMed ID: 31550809
[No Abstract] [Full Text] [Related]
44. Nuclear interacting SET domain protein 1 inactivation impairs GATA1-regulated erythroid differentiation and causes erythroleukemia.
Leonards K; Almosailleakh M; Tauchmann S; Bagger FO; Thirant C; Juge S; Bock T; Méreau H; Bezerra MF; Tzankov A; Ivanek R; Losson R; Peters AHFM; Mercher T; Schwaller J
Nat Commun; 2020 Jun; 11(1):2807. PubMed ID: 32533074
[TBL] [Abstract][Full Text] [Related]
45. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.
Morishita M; Mevius D; di Luccio E
BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638
[TBL] [Abstract][Full Text] [Related]
46.
Berardi A; Ghitti M; Quilici G; Musco G
Comput Struct Biotechnol J; 2020; 18():4082-4092. PubMed ID: 33363704
[TBL] [Abstract][Full Text] [Related]
47. Systematic perturbations of SETD2, NSD1, NSD2, NSD3 and ASH1L reveals their distinct contributions to H3K36 methylation.
Shipman GA; Padilla R; Horth C; Hu B; Bareke E; Vitorino FN; Gongora JM; Garcia BA; Lu C; Majewski J
bioRxiv; 2023 Oct; ():. PubMed ID: 37905045
[TBL] [Abstract][Full Text] [Related]
48. Spectrum of NSD1 mutations in Sotos and Weaver syndromes.
Rio M; Clech L; Amiel J; Faivre L; Lyonnet S; Le Merrer M; Odent S; Lacombe D; Edery P; Brauner R; Raoul O; Gosset P; Prieur M; Vekemans M; Munnich A; Colleaux L; Cormier-Daire V
J Med Genet; 2003 Jun; 40(6):436-40. PubMed ID: 12807965
[TBL] [Abstract][Full Text] [Related]
49. Expression and prognostic value of NSD1 and SETD2 in pancreatic ductal adenocarcinoma and its precursor lesions.
Ettel M; Zhao L; Schechter S; Shi J
Pathology; 2019 Jun; 51(4):392-398. PubMed ID: 31060750
[TBL] [Abstract][Full Text] [Related]
50. Dasatinib and navitoclax act synergistically to target NUP98-NSD1
Kivioja JL; Thanasopoulou A; Kumar A; Kontro M; Yadav B; Majumder MM; Javarappa KK; Eldfors S; Schwaller J; Porkka K; Heckman CA
Leukemia; 2019 Jun; 33(6):1360-1372. PubMed ID: 30568173
[TBL] [Abstract][Full Text] [Related]
51. Cryptic insertion producing two NUP98/NSD1 chimeric transcripts in adult refractory anemia with an excess of blasts.
La Starza R; Gorello P; Rosati R; Riezzo A; Veronese A; Ferrazzi E; Martelli MF; Negrini M; Mecucci C
Genes Chromosomes Cancer; 2004 Dec; 41(4):395-9. PubMed ID: 15382262
[TBL] [Abstract][Full Text] [Related]
52. Auxological data in patients clinically suspected of Sotos syndrome with NSD1 gene alterations.
de Boer L; le Cessie S; Wit JM
Acta Paediatr; 2005 Aug; 94(8):1142-4. PubMed ID: 16188863
[TBL] [Abstract][Full Text] [Related]
53. Spectrum of NSD1 gene mutations in southern Chinese patients with Sotos syndrome.
Tong TM; Hau EW; Lo IF; Chan DH; Lam ST
Chin Med J (Engl); 2005 Sep; 118(18):1499-506. PubMed ID: 16232326
[TBL] [Abstract][Full Text] [Related]
54. Mutations in the NSD1 gene in patients with Sotos syndrome associate with endocrine and paracrine alterations in the IGF system.
De Boer L; Van Duyvenvoorde HA; Willemstein-Van Hove EC; Hoogerbrugge CM; Van Doorn J; Maassen JA; Karperien M; Wit JM
Eur J Endocrinol; 2004 Sep; 151(3):333-41. PubMed ID: 15362962
[TBL] [Abstract][Full Text] [Related]
55. Structural insights into the regulation and the recognition of histone marks by the SET domain of NSD1.
Morishita M; di Luccio E
Biochem Biophys Res Commun; 2011 Aug; 412(2):214-9. PubMed ID: 21806967
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of NSD2 and NSD3 in overgrowth syndromes.
Douglas J; Coleman K; Tatton-Brown K; Hughes HE; Temple IK; Cole TR; Rahman N;
Eur J Hum Genet; 2005 Feb; 13(2):150-3. PubMed ID: 15483650
[TBL] [Abstract][Full Text] [Related]
57. Dynamic behavior of the post-SET loop region of NSD1: Implications for histone binding and drug development.
Graham SE; Tweedy SE; Carlson HA
Protein Sci; 2016 May; 25(5):1021-9. PubMed ID: 26940890
[TBL] [Abstract][Full Text] [Related]
58. MLPA analysis in 30 Sotos syndrome patients revealed one total NSD1 deletion and two partial deletions not previously reported.
Fagali C; Kok F; Nicola P; Kim C; Bertola D; Albano L; Koiffmann CP
Eur J Med Genet; 2009; 52(5):333-6. PubMed ID: 19596467
[TBL] [Abstract][Full Text] [Related]
59. CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia.
Schmoellerl J; Barbosa IAM; Eder T; Brandstoetter T; Schmidt L; Maurer B; Troester S; Pham HTT; Sagarajit M; Ebner J; Manhart G; Aslan E; Terlecki-Zaniewicz S; Van der Veen C; Hoermann G; Duployez N; Petit A; Lapillonne H; Puissant A; Itzykson R; Moriggl R; Heuser M; Meisel R; Valent P; Sexl V; Zuber J; Grebien F
Blood; 2020 Jul; 136(4):387-400. PubMed ID: 32344427
[TBL] [Abstract][Full Text] [Related]
60. NSD1 in erythroid differentiation and leukemogenesis.
Tauchmann S; Almosailleakh M; Schwaller J
Mol Cell Oncol; 2020 Sep; 7(6):1809919. PubMed ID: 33235911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
